<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915873</url>
  </required_header>
  <id_info>
    <org_study_id>BS in VWD</org_study_id>
    <nct_id>NCT03915873</nct_id>
  </id_info>
  <brief_title>Evaluation of Bleeding Score in Egyptian Patients With vWD Type I and Correlate it With Laboratory Parameters</brief_title>
  <official_title>Assessing the Bleeding Severity in Type I Von Willebrand Patients Using the International Society on Thrombosis and Hemostasis Bleeding Assessment Tool ( ISTH-BAT) Questionnaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Applying the ISTH-BAT questionnaire on Egyptian patients with type I VWD aiming to correlate
      the BS with the laboratory findings
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical phenotype of the disease is variable and tends to be mild in type 1 vWD, whereas
      it shows serious bleeding manifestations in types 2 and 3. Overall, the symptoms reported in
      vWD include easy bruising, epistaxis, gastrointestinal bleeding, excessive menstrual
      bleeding, postpartum haemorrhage, and excessive bleeding after surgical operation and minor
      wounds.However, A distinctive bleeding history is a prerequisite for the diagnosis of any
      bleeding disorder and should guide further laboratory investigations In an attempt to
      standardize the diagnostic criteria of VWD, a bleeding questionnaire and a bleeding score
      were developed The combination of a standardized bleeding questionnaire and a well-defined
      interpretation grid (for the computation of the final (BS) has been referred to as a Bleeding
      Assessment Tool (BAT).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the International Society on Thrombosis and Hemostasis-Bleeding Assessment Tool (ISTH-BAT)</measure>
    <time_frame>one year</time_frame>
    <description>Questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Von Willebrand Disease, Type 1</condition>
  <arm_group>
    <arm_group_label>vWB patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>The von Willebrand Antigen level</intervention_name>
    <description>blood sample</description>
    <arm_group_label>vWB patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        type 1 von willebrand egyptian patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 vWD patients

          -  healthy subjects with no known problem with bleeding or bruising were also recruited

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>September 7, 2019</last_update_submitted>
  <last_update_submitted_qc>September 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>shery nabil Hennes abdl-sayed</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>von willebrand</keyword>
  <keyword>egyptian</keyword>
  <keyword>questionnaire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
    <mesh_term>Von Willebrand Disease, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

